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large case-control whole-genome scan at over 500,000
polymorphisms which presents weak evidence for associa-
tion and potentially narrows the association interval. 
 Copyright © 2007 S. Karger AG, Basel 
 
Alzheimer’s disease (AD) is a neurodegenerative dis-
order characterized by progressively disabling impair-
ments in memory and other cognitive domains, but also 
by non-cognitive behavioural symptoms. AD preferen-
tially affects individuals over 60 years with prevalence 
rates as high as 40% in nonagenarians  [1] . Sporadic AD is 
multifactorial and genetically complex. Twin studies sug-
gest that genetic factors may account for as much as 80% 
of the disease risk  [2] . While several monogenic muta-
tions cause early-onset AD and gene alleles have been 
suggested as AD susceptibility factors, the only exten-
sively validated susceptibility gene for AD is the apolipo-
protein E  (APOE)   4 allele  [3, 4] . Alleles of the  APOE gene 
do not account for all of the genetic load calculated to be 
responsible for AD predisposition. Recently, Rogaeva et 
al.  [5] reported polymorphisms across the neuronal sor-
 Key Words 
 Sorl1   Alzheimer’s disease   Predisposition gene    APOE 
gene   Sortilin-related receptor 
 Abstract 
 Alzheimer’s disease (AD) is a neurodegenerative disorder 
characterized by progressively disabling impairments in 
memory, cognition, and non-cognitive behavioural symp-
toms. Sporadic AD is multifactorial and genetically complex. 
While several monogenic mutations cause early-onset AD 
and gene alleles have been suggested as AD susceptibility 
factors, the only extensively validated susceptibility gene for 
late-onset AD is the apolipoprotein E  (APOE)   4 allele. Alleles 
of the  APOE gene do not account for all of the genetic load 
calculated to be responsible for AD predisposition. Recently, 
polymorphisms across the neuronal sortilin-related receptor 
 (SORL1) gene were shown to be significantly associated with 
AD in several cohorts. Here we present the results of our 
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tilin-related receptor  (SORL1) gene to be significantly as-
sociated with AD in several cohorts.
 A genome-wide association study was performed us-
ing 502,627 SNPs on DNA samples extracted from brain 
tissue of donors who were at least 65 years of age at the 
time of their death. The donors included 664 patients 
who satisfied clinical and neuropathological criteria for 
the diagnosis of AD and 422 persons that did not meet 
clinical or neuropathological criteria for AD as controls. 
Their brain tissue and neuropathological diagnoses 
were supplied by investigators from 20 National Insti-
tute on Aging Alzheimer’s Disease Centers (ADCs) in 
accordance with an agreement with these Centers, the 
National Institute on Aging, and the National Alzhei-
mer’s Coordinating Center (NACC). Additional post-
mortem samples were received from Sun Health Re-
search Institute and The Netherlands Brain Bank. In 
addition to a neuropathologist’s diagnostic decision, 
18% of the patients and 16% of controls were assessed 
using CERAD criteria, which provide information about 
neuritic plaque density  [6] . 59% of the patients and 75% 
of the controls were also assessed using Braak and Braak 
staging  [7] , which assesses the distribution of neurofi-
brillary tangles  [6] . The patients included 362 females 
and 302 males, and averaged 82  8 7.7 years of age at the 
time of death. The controls included 255 females and 
167 males, and averaged 79  8 11.0 years of age at the 
time of death. The software program STRUCTURE was 
used to test for underlying genetic stratification, using 
5,000 randomly selected SNPs with at least 100 per chro-
mosome. Initial analysis yielded empirical evidence of 
three populations. One, which contained 14 samples 
and was far removed from the rest of the study popula-
tion, was removed from further analyses. STRUCTURE 
was re-run with K = 2, and each sample was assigned an 
admixture of the resulting populations. Comparison of 
the resulting case and control populations defined by 
these admixture vectors yielded a silhouette score of 
0.06. This indicates that while the samples in this study 
are likely to be the result of admixture of two popula-
tions, the distribution of those populations is equivalent 
in cases and controls  [8] . As previously reported  [9] , the 
most significant SNP identified through Fisher’s exact 
tests through the scan, rs4420638 (uncorrected p val -
 ue = 1.06  ! 10 –39 , Bonferonni corrected p value for mul-
tiple hypothesis testing = 5.30  ! 10 –34 based on 500,000 
comparisons), which was located on chromosome 19, 14 
kb from the  APOE   4 variant, speaking to the technical 
robustness of the whole-genome association strategy at 
this SNP density.
 The hypothesis that a specific allele of  SORL1 is asso-
ciated with increased AD risk was tested. The 46 SNPs 
located in the  SORL1 genomic locus on the Affymetrix 
500K Mapping Array were directly targeted for signifi-
cance analysis in our whole-genome data set, and thus no 
multiple-testing correction was applied to the signifi-
cance values. Calculation of a SNP’s allelic frequency dif-
ferences between cases and controls was based on the 
Fisher’s exact test using each contiguous SNP within the 
gene sequentially.  Table 1 identifies four SNPs with p  ! 
0.05 between chromosome 11 SNPs rs668387 (120,873,131 
bp) and rs1790208 (120,932,469 bp). This region overlaps 
the Rogaeva et al. significant region from rs668387 
(120,873,131 bp) to rs12285364 (120,898,436 bp). The risk-
associated alleles are presented in  table 1 , and articulate 
a 59-kb interval, which encompasses 12 exons (exons 7 
through 18) of the  SORL1 gene. Of the 9 significant SNPs 
in Rogaeva et al., 3 were directly measured in our study 
and each of the remaining 6 are in LD with at least 1 SNP 
on the Affymetrix Array ( fig. 1 )  [5] . Thus we have cap-
tured all of the significant SNPs from the Rogaeva et al. 
study, including those we have not directly measured. Po-
tentially problematic is that SNPs rs7131432 and rs2101756 
have very rare minor allele frequencies (1.6 and 0.5% re-
spectively) and thus the p values are very sensitive to sub-
tle distribution differences, residual genotype error, and 
subtle stratification between cases and controls and 
should be interpreted with caution. We do not see sig-
nificant association with the SNPs that were reported in 
Rogaeva et al. that were present on the Affymetrix 500k 
SNP array (in italics in  table 1 , significant SNPs from Ro-
gaeva et al. underlined), nor do we see significance at the 
3  region of the locus noted in the original report  [5] . The 
5  region of the locus shows nominally significant repli-
cation with low odds ratio (OR) of 1.551 at rs11218313 
(maximum value of the four associated SNPs with MAF 
 1 2%, and in contrast to an OR of 4 for  APOE  4 hetero-
zygotes, and 15–20 for homozygotes). Of note, we would 
not see these effects if we corrected for multiple testing by 
Bonferoni. Replication of only one region of the SORL1 
locus is consistent with the findings of Rogaeva et al. Sig-
nificance of this locus in our population using a different 
series of SNPs than the original report potentially gives 
insight into SORL1-mediated biology, and refining the 
association signal to 59 kb could help to narrow the search 
for disease causing alleles. Whole-genome association 
studies using well-phenotyped and well-powered study 
designs may provide disparate results for subtle allelic as-
sociation findings, such as SORL1. The importance of the 
 SORL1 finding is also that it articulates a common prob-
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Table 1. Fisher’s exact p values across the SORL1 locus from a whole-genome association scan using 1,086 AD 
cases and controls
dbSNP RS ID Position p value Risk 
allele
MAF OR (95% CI)
rs4935774 120826964 0.8094 0.209
rs17125349 120829417 0.2355 0.077
rs610188 120834606 0.415 0.038
rs1784934 120843203 0.5133 0.331
rs676160 120845443 0.3994 0.094
rs676759 120864475 0.6479 0.383
rs560573 120866094 0.119 0.38
rs2298525 120866225 0.8829 0.098
rs985421 120867526 0.343 0.012
rs9665981 120869213 0.6092 0.382
rs12364988 120872836 0.3524 0.486
rs668387 120873131 0.5226 0.422
rs2101756 120874460 0.01923 C 0.005 1.19 (0.866–1.74)
rs11218313 120888081 0.02026 C 0.118 1.55 (0.756–2.12)
rs17125423 120909761 0.3375 0.003
rs626885 120914166 0.03616 T 0.479 1.19 (0.968–1.42)
rs2276346 120919686 0.09332 0.355
rs10502262 120920522 0.106 0.283
rs7131432 120932080 0.03869 A 0.016 1.73 (0.998–3.67)
rs1790208 120932469 0.3479 0.001
rs11218340 120936564 0.6076 0.143
rs10892756 120939766 0.7295 0.075
rs11218343 120940797 0.6357 0.082
rs11218346 120944391 0.4664 0.081
rs1792124 120946730 0.6149 0.017
rs1790213 120947399 0.2949 0.385
rs11218347 120951758 0.7815 0.077
rs1699103 120957136 0.8596 0.42
rs7116734 120957150 0.1016 0.408
rs1792127 120957244 0.1566 0.001
rs11218350 120957861 0.7873 0.227
rs10892759 120969298 0.1122 0.341
rs7127359 120970156 0.6789 0.358
rs11218360 120978601 0.9359 0.031
rs7128608 120978808 0.946 0.034
rs1629493 120982306 0.2664 0.381
rs2282648 120983705 0.2016 0.339
rs2282649 120984168 0.97 0.285
rs726601 120986617 0.19 0.308
rs1784931 120988148 0.1377 0.397
rs1010159 120988611 0.2545 0.355
rs1503413 120992024 0.5687 0.057
rs1614735 120998211 0.4347 0.471
rs17125558 120999237 0.7932 0.025
rs17125561 120999299 0.4623 0.004
rs10892761 121003094 0.4663 0.412
SNPs highlighted in bold are significant in our population, SNPs italicized are those reported in the Ro-
gaeva et al. study populations, and those that are underlined are reported as significant by Rogaeva et al.
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lem with low OR associations in that power, population 
structure and history, allelic heterogeneity and SNP cov-
erage across the locus may confound the ability to tease 
out subtle allelic associations in complex traits. If SORL1 
does demonstrate allelic heterogeneity, the presence of 
the admixture of two populations that STRUCTURE re-
vealed for our study population could dilute any associa-
tion signals that were present in the two original popula-
tions. Clearly our results can be interpreted either as a 
failure to replicate or as a partial replication depending 
on one’s point of view and this illustrates a current major 
problem in association studies. Even analyses in large, 
well-characterized studies such as ours fail to give signals 
clear enough to distinguish between no signal and vari-
able signals in different cohorts.
 Acknowledgements 
 Sponsors: Kronos Life Sciences Laboratories, The Arizona 
 Alzheimer’s Disease Core Center (P30 AG19610), the National 
Alzheimer’s Coordinating Center (U01 AG016976), and the State 
of Arizona. We thank Drs. Creighton Phelps, Marcelle Morrison-
Bogorad, Marilyn Miller, and Walter Kukull for their assistance 
in the acquisition of tissue samples and data. None of this work 
 Fig. 1. Out of the nine markers in SORL1 found to be significantly associated with disease risk in Rogaeva et al. 
 [5] , we have typed three of those markers (black rectangles). To examine whether we were able to capture the 
remaining 6 significant SNPs typed from the Rogaeva screen (black circles), we mapped the LD relationships 
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